Drug Therapies

Antibody-drug conjugates (ADCs) offer a unique approach for the treatment of solid tumors and hematologic cancers. The idea is that a potent cytotoxic agent is linked to an antibody specifically targeted to tumor cells, and once the antibody binds to the tumor cell, the cytotoxic agent is unleashed inside the cells to attack the cancer. Read More ›

Patients with HER2+ breast cancer who develop resistance to trastuzumab may soon have an alternative therapy, according to recent findings published in Clinical Cancer Research.

Read More ›

Tissue velocity imaging and strain imaging can predict preclinical changes in left ventricular (LV) systolic function before a patient experiences a change in left ventricular ejection fraction (LVEF), according to a prospective study in HER2-positive patients receiving trastuzumab in the adjuvant setting. Cardiac biomarkers, however, did not predict the development of cardiac dysfunction. Read More ›

Asmall Canadian study found that patients who took delta-9- tetrahydrocannabinol (THC), the psychoactive ingredient in marijuana, slept better and derived more enjoyment from eating than patients given a placebo. The University of Alberta investigators, led by associate professor Wendy Wismer, recruited terminal patients with advanced cancer who were randomly assigned to take 2.5 mg of dronabinol (a pill form of THC) or placebo twice daily for 18 days. Afterward, the participants completed questionnaires to assess whether their quality of life improved during the study.

Read More ›

The Centers for Medicare & Medi caid Services (CMS) has released a proposed decision memo that suggests it will cover the cost of sipuleucel-T (Provenge), the immunotherapy vaccine approved in April 2010 for men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer, for on-label use. CMS contractors will have discretion as to whether they will cover it for off-label use.

Read More ›

Patients with inoperable metastatic melanoma now have another treatment option as ipilimumab becomes the second immunotherapy drug approved by the US Food and Drug Administration (FDA) for the treatment of cancer. Read More ›

The somatostatin analog lanreotide (Somatuline) reduced the frequency of vomiting for patients with inoperable malignant bowel obstruction (MBO) in what presenter Pascale Mariani, MD, at the Institut Curie in Paris, France, called the first randomized, doubleblind, placebo-controlled study on palliative care in this patient population. Read More ›

SAN ANTONIO—For women with human epidermal growth factor receptor type 2 (HER2)-overexpressing breast cancer, preoperative treatment with agents that block HER2 leads to high rates of pathological complete response (pCR), according to the results of three studies presented at the 33rd annual San Antonio Breast Cancer Symposium.  Read More ›

High doses of vitamin D can relieve musculoskeletal pain associated with aromatase inhibitors (AIs) in women with breast cancer, according to a study presented at the 32nd Annual San Antonio Breast Cancer Symposium in San Antonio, Texas.

Read More ›

Diastolic blood pressure (dBP) ≥90 mm Hg may identify whether a patient will benefit from therapy with axitinib, a selective inhibitor of vascular endothelial growth factor (VEGF) receptors, a new study suggests.

Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: